About 2025 Event

Welcome to the 4th In Vivo Cell Engineering & Gene Editing Summit!

Join this forum with other in vivo cell and gene enthusiasts, C-Level Executives, Vice Presidents and Directors, dedicated to progressing in vivo CAR, mRNA and gene editing therapies to expanding therapeutic options and treatment accessibility.  

With an 82% new speaker faculty highlighting strategies to decrease variability of translational outcomes, de-target the liver and expand treatment possibilities and 12 new companies showcasing the latest innovations and technologies to progress the in vivo cell and gene field, this summit is the must attend event in the cell and gene space to progress the development of safe, targeted in vivo delivery of your therapeutic modality.    

Register

Join Pioneers in In Vivo Cell Engineering & Gene Editing To:

Uncover new research into drug and tissue targeting approaches, delivery vehicle optimization and the latest IND data to enhance treatment specificity and overcome off-target toxicity with NanoCell Therapeutics, Alaya.Bio, Cytodigm, Singular Immune, Ensoma and Capstan Therapeutics
Identify effective preclinical models to ensure effective translatable data and streamline the IND approval process with Carisma Therapeutics and Exuma Biotech
Pinpoint the most effective delivery vehicle for your CAR, mRNA or gene editing treatment to combat off-target and delivery system toxicity with Beam Therapeutics, NanoCell Therapeutics, Singular Immune and AbbVie
Clarify regulatory requirements in this everchanging space to achieve safety and efficacy data for your therapy and navigate the path to the clinic with insights from Umoja Biopharma and CorriXR Therapeutics
Gain insights into an investors mindset to ensure the commercial viability of your treatments and facilitate collaboration and investment opportunities with Qiming Venture Partners
View the Agenda

Who Can You Meet?

2024 Companies - 1100x300

Hear from the 2024 Attendees

‘There was a good variety of topics and approaches discussed by presenters in relation to the in vivo space. Having experienced and established presenters was helpful to those newer to the space.’

Amanda Toreki, Associate Scientist, Cabaletta Bio

‘Great speakers, relevant companies, with some new smaller companies getting exposure and intimate setting for networking.’

Michael Klichinsky, Co-Founder & Chief Scientific Officer, Carisma Therapeutics

‘The small nature of the conference made for a very nice opportunity to network with others in the field and share our experiences, future expectations, and concerns about the field.’

Matthew Spindler, Vice President, Research, GigaMune

‘The lectures as well as the discussions were very relevant and interesting. The forum in which it was conducted was great, it allowed for questions and discussions.’

Hangmesh Cassim, Associate Scientist, Cabaletta Bio

"The conference was nicely organized, represented by key opinion leaders in the field and small but engaging audience. That made the discussion very fruitful."

Dharini Shah, Senior Director, Research & Immunology, Sanofi

Download the 2025 Agenda for More Information on:

    • 17+ In Vivo Expert Speakers
    • 2 Interactive Deep-Dive Workshops
    • 8+ Hours of Industry Networking
    • & Much More!
View the Agenda
58621 - Agenda Cover - 604x855
2025 Agenda
Register
Become a Partner